Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Articles
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 14th 2022Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Read More
ASH 2021: Key Data in Chronic Myeloid Leukemia
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 7th 2022Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Read More
ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
January 31st 2022Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Read More
